NetworkNewsBreaks – Predictive Oncology (NASDAQ:
Post# of 281
(Total Views: 208)
Posted On: 01/14/2021 3:04:53 PM
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced an additional order that came from a private company conducting research on ovarian cancer. Experts forecast that the 3D cancer cell culture media market will grow at CAGR of approximately 11.3%, reaching $3.2 billion in sales in worldwide by 2027. According to the announcement, the reason for the significant growth is because older technologies do not generally reproduce a patient’s tumor cell populations, and immortalized cells, or cells that live forever and are altered from the original tumor, do not make good models for use in drug discovery and development. The company called the idea of replicating ovarian cancer cells outside of a patient’s body and in a laboratory well plate or culture flask remarkable. “We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said POAI president and CEO Dr. Carl Schwartz in the press release. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step. Then we can focus on how to kill them.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced an additional order that came from a private company conducting research on ovarian cancer. Experts forecast that the 3D cancer cell culture media market will grow at CAGR of approximately 11.3%, reaching $3.2 billion in sales in worldwide by 2027. According to the announcement, the reason for the significant growth is because older technologies do not generally reproduce a patient’s tumor cell populations, and immortalized cells, or cells that live forever and are altered from the original tumor, do not make good models for use in drug discovery and development. The company called the idea of replicating ovarian cancer cells outside of a patient’s body and in a laboratory well plate or culture flask remarkable. “We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said POAI president and CEO Dr. Carl Schwartz in the press release. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step. Then we can focus on how to kill them.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)